Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: The txt2heart Colombia randomised controlled trial protocol
Fecha
01/01/2019
Autores
Bermon A.
Uribe-Rodríguez A.F.
Pérez-Rivero P.F.
Prieto-Merino D.
Caceres Rivera, Diana
Guio E.
Atkins L.
Horne R.
Murray E.
Serrano DÍaz N.C.
Título de la revista
ISSN de la revista
Título del volumen
Editor
BMJ Publishing Group
Resumen
Palabras clave
11 OXOTHROMBOXANE B2 , ADULT , ANGIOTENSIN RECEPTOR ANTAGONIST , ARTICLE , ATORVASTATIN , BEHAVIOR CHANGE , BETA ADRENERGIC RECEPTOR BLOCKING AGENT , BLOOD , CARDIOVASCULAR AGENT , CONTROLLED STUDY , CORONARY ARTERY ATHEROSCLEROSIS , DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR , FLUINDOSTATIN , HEART RATE , HUMAN , HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR , LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL , MEDICATION COMPLIANCE , PATIENT COMPLIANCE , PRAVASTATIN , PROGRAM EFFICACY , RANDOMIZED CONTROLLED TRIAL , ROSUVASTATIN , SECONDARY PREVENTION , SELF REPORT , SIMVASTATIN , SINGLE BLIND PROCEDURE , SYSTOLIC BLOOD PRESSURE , TEXT MESSAGING